The ClpP activator ONC‐212 (TR‐31) inhibits BCL2 and B‐cell receptor signaling in CLL

Despite advances in therapy, a significant proportion of patients with chronic lymphocytic leukemia (CLL) relapse with drug resistant disease. Novel treatment approaches are required, particularly for high risk disease. The imipridones represent a new class of cancer therapy that has been investigat...

Descripción completa

Detalles Bibliográficos
Autores principales: Fatima, Narjis, Shen, Yandong, Crassini, Kyle, Iwanowicz, Edwin J., Lang, Henk, Karanewsky, Donald S., Christopherson, Richard I., Mulligan, Stephen P., Best, Oliver G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Haematologic Malignancy ‐ Lymphoid
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175891/
https://www.ncbi.nlm.nih.gov/pubmed/35846080
http://dx.doi.org/10.1002/jha2.160

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175891/
https://www.ncbi.nlm.nih.gov/pubmed/35846080
http://dx.doi.org/10.1002/jha2.160

Ejemplares similares